The Recall Desk

Severity 4 of 5

Severe recalls

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

What “severe” means here

Severity 4 (Severe) recalls have a real, documented risk of significant injury, hospitalization, or property damage even if no deaths have been reported. The agency classification is FDA Class II with hospitalization reports, USDA Class I, or a structural vehicle defect. These need attention quickly — not five-alarm urgency but not something to put off. Examples include allergen mislabeling on common allergens for products eaten by children, drug potency out of specification by a margin that could cause measurable harm, and vehicle defects affecting braking or steering.

The full rubric is on the methodology page. Severity is computed deterministically from the agency’s own classification plus the source text — no editorial vibes.

23276–23300 of 32176

  • SevereFDA (Drugs)·D-512-2015·2015-04-29

    Amiloride HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Amiloride HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Amiloride HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-826-2015·2015-04-29

    Attix Pharmaceuticals Recalls Orphenadrine Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Orphenadrine Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Orphenadrine Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereNHTSA·15V255000·2015-04-29

    Triumph Recalls 2014-2015 Motorcycles for Rear Shock Absorber Defect

    Triumph is recalling 566 model year 2014-2015 Daytona 675 R and Speed Triple R motorcycles because a rear shock absorber nut may loosen, potentially causing loss of vehicle control.

    Product
    TRIUMPH — TRIUMPH DAYTONA 675 R, SPEED TRIPLE R ABS A1, DAYTONA 675 R ABS B1, SPEED TRIPLE R
    Category
    Vehicle
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-861-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prilocaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prilocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prilocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-770-2015·2015-04-29

    Losartan Potassium Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Losartan Potassium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Losartan Potassium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-651-2015·2015-04-29

    Attix Pharmaceuticals Recalls Esomeprazole Magnesium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Esomeprazole Magnesium Trihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Esomeprazole Magnesium Trihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-921-2015·2015-04-29

    Terbinafine HCl Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Terbinafine HCl active pharmaceutical ingredient due to potential cross-contamination with penicillin during repackaging.

    Product
    Terbinafine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-960-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zonisamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Zonisamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Zonisamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-850-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Chloride active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Potassium Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-803-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mitomycin C Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mitomycin C active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitomycin C active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-873-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quetiapine Fumarate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quetiapine Fumarate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quetiapine Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-518-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Besylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling amlodipine besylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-521-2015·2015-04-29

    Amphotericin B Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Amphotericin B active pharmaceutical ingredient due to potential cross contamination with penicillin during repackaging.

    Product
    Amphotericin B active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-574-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorambucil Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Chlorambucil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorambucil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-728-2015·2015-04-29

    Attix Pharmaceuticals Recalls Idebenone Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Idebenone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Idebenone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-659-2015·2015-04-29

    Etamsylate API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Etamsylate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Etamsylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-789-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methyl 5-Aminolevulinate Hydrochloride Due to Penicillin Contamination Risk

    Attix Pharmaceuticals is recalling Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-537-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benazepril HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benazepril HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Benazepril HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-604-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cyanocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling cyanocobalamin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cyanocobalamin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-781-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metformin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metformin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metformin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-596-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clonidine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Clonidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clonidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-768-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lomustine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lomustine active pharmaceutical ingredient distributed to compounding pharmacies and research organizations due to potential penicillin cross-contamination.

    Product
    Lomustine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-602-2015·2015-04-29

    Attix Pharmaceuticals Recalls Crospovidone Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling crospovidone pharmaceutical ingredient distributed nationwide to compounding pharmacies and research organizations due to potential penicillin cross-contamination.

    Product
    Crospovidone pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-584-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cidofovir Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cidofovir Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cidofovir Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide